Sarepta Therapeutics (SRPT) Misses Q1 EPS by 24c, Revenue Beats

Sarepta Therapeutics (NASDAQ: SRPT) reported Q1 EPS of ($0.60), $0.24 worse than the analyst estimate of ($0.36). Revenue for the quarter came in at $16.3 million versus the consensus estimate of $13.86 million.

Company anticipates net revenues for the year will exceed $95 million

(Street sees FY rev of $95.8M)

For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.

You May Also Be Interested In

• United Natural Foods (UNFI) Tops Q4 EPS by 8c ; Offers Guidance
• JPMorgan starts FedEx Freight at Overweight on post-spin turnaround
• Labcorp acquires MLM Medical Labs to expand lab network